All In Biotech

Drug Trial Radar · NCT07377643

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

A Randomized, Multicenter, Open-label Phase 3 Study to Compare IBI354 With or Without Pertuzumab vs. Taxane in Combination With Trastuzumab and Pertuzumab as First-line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Apr 28, 2028

Study completion May 31, 2030

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multicenter, open-label, phase 3 study evaluating the efficacy, safety, and tolerability of IBI354 combined with or without pertuzumab vs. THP as first-line treatment for HER2-positive unresectable, locally advanced or metastatic breast cancer.

Conditions

  • HER2-positive Breast Cancer

Interventions

  • TrastuzumabDrug

    IV infusion

  • IBI354Drug

    IV infusion

  • DocetaxelDrug

    IV infusion

  • PertuzumabDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessmentTime frame: Until progression or death, up to 54 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.